Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review

References

• Wang Z, Yang B, Li Q, et al. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020;71(15):769–777.
   PubMed Web of Science ®Google Scholar
• Liu K, Fang Y-Y, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020;133(9):1025–1031.
   PubMed Web of Science ®Google Scholar
• Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
   PubMed Web of Science ®Google Scholar
• Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949
   PubMed Web of Science ®Google Scholar
• Sarkar C, Mondal M, Torequl IM, et al. Potential therapeutic options for COVID-19: current status, challenges, and future perspectives. Front Pharmacol. 2020;11:572870.
   PubMed Web of Science ®Google Scholar
• WHO. WHO welcome to the WHO ICTRP; 2020. Available from: https://www.who.int/clinical-trials-registry-platform2020.
   Google Scholar
• Aronson JK, Ferner RE, DeVito N, et al. COVID-19 registered trials – and analysis – CEBM;2020.
   Google Scholar
• NIH National Heart, Lung and Blood Institute. Study quality assessment tools; 2020. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.
   Google Scholar
• Connolly MP, Haitsma G, Hern´Andez AV, et al. Systematic review and meta-analysis of secondary prophylaxis for prevention of HIV-related toxoplasmic encephalitis relapse using trimethoprim-sulfamethoxazole. Pathog Glob Health. 2017;111(6):327–331.
   PubMed Web of Science ®Google Scholar
• Leng Z, Rongjia Z, Wei H, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216–228.
   PubMed Web of Science ®Google Scholar
• Ye X, Luo Y, Xia S, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 2020;24(6):3390–3396.
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020;382(19):1787–1799.
   PubMed Web of Science ®Google Scholar
• Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. medRxiv Prepr. 2020.
   Google Scholar
• Runuan W, Nanhong Z, Xiang J, et al. Multi-center, prospective study of early Abidor + lopinavir/ritonavir + recombinant interferon alpha-2b combined antiviral therapy in patients with coronavirus pneumonia. Chin J Clin Infect Dis. 2020:13.
   Google Scholar
• Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv.
   Google Scholar
• Chen J, Liu D, Liu L, et al. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):215–219. (Chinese).
   PubMedGoogle Scholar
• Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020;6(10):1192–1198.
   Web of Science ®Google Scholar
• Jun C, Danping L, Li L, et al. Preliminary study of hydroxychloroquine sulfate in patients with common 2019 coronavirus disease (COVID-19). J Zhejiang Univ. 2020;49:215–219.
   Google Scholar
• Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;2019(March):1–5.
   Google Scholar
• Jun C, Yun L, Xiuhong X, et al. Efficacy of lopinavir, ritonavir and abidor for the treatment of new corona virus pneumonia. J Chin J Infect Dis. 38:E008.
   Google Scholar
• Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847.
   PubMed Web of Science ®Google Scholar
• Zheng F, Liao C, Fan Q-h, et al. Clinical characteristics of children with coronavirus disease 2019 in Hubei, China. Curr Med Sci. 2020;40(2):275–280.
   PubMed Web of Science ®Google Scholar
• Sun D, Li H, Lu XX, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study. World J Pediatr. 2020;16(3):251–259.
   PubMed Web of Science ®Google Scholar
• Duan W, Xiuli J, Feng X, et al. Clinical analysis of 31 cases of 2019 new coronavirus infection in children from six provinces (autonomous regions) in northern China. Chinese J Pediatr. 2020.
   Google Scholar
• Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med. 2020;382(24):2327–2336.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier J-C, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020;34:101663.
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen X, Lu Y, et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020;14(1):64–68.
   PubMed Web of Science ®Google Scholar
• Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest. 2020;158(1):e9–e13.
   PubMed Web of Science ®Google Scholar
• Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1588.
   PubMed Web of Science ®Google Scholar
• Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020;92(7):814–818.
   PubMed Web of Science ®Google Scholar
• Chen J-Y, Qiao K, Liu F, et al. Lung transplantation as therapeutic option in acute respiratory distress syndrome for COVID-19-related pulmonary fibrosis. Chin Med J. 2020;133(12):1390–1396.
   PubMed Web of Science ®Google Scholar
• Dan L, Hongyan L, Yan W, et al. Analysis of clinical characteristics of 30 cases of new coronavirus pneumonia. Chin J Infect Dis. 2020.
   Google Scholar
• Shi C, Wu JJ, Li MZ, et al. Clinical features of 109 cases of novel coronavirus pneumonia. Chin J Infect Dis. 38:E015.
   Google Scholar
• Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. 2020;18(7):1752–1755.
   PubMed Web of Science ®Google Scholar
• Ebada MA, Wadaa-Allah A, Bahbah E, et al. An updated review on COVID-19. Infect Disord Drug Targets. 20. Doi: 10.2174/1871526520666201216165322
   Google Scholar
• Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting the results. Expert Rev Mol Diagn. 2020;20(5):453–454.
   PubMed Web of Science ®Google Scholar
• Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732–739.
   PubMed Web of Science ®Google Scholar
• Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16
   PubMed Web of Science ®Google Scholar
• Taccone FS, Gorham J, Vincent J-L. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med. 2020;8(6):539–541.
   PubMed Web of Science ®Google Scholar
• Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449–463.
   PubMed Web of Science ®Google Scholar
• Cao W, Liu X, Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020;7(3):ofaa102.
   PubMed Web of Science ®Google Scholar
• Ebada MA, Fayed N, Alkanj S, et al. Enterovirus D-68 molecular virology, epidemiology, and treatment: an update and way forward. Infect Disord Drug Targets. 20.
   Google Scholar
• Dan L, Hongyan L, Yan W, et al. Analysis of clinical characteristics of 30 cases of new coronavirus pneumonia. J Chem Inf Model. 2020;53(9):1689–1699.
   Google Scholar
• Blaising J, Polyak SJ, Pécheur E-I. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014;107:84–94.
   PubMed Web of Science ®Google Scholar
• Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695–1704.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395(10236):1569–1578.
   PubMed Web of Science ®Google Scholar
• Scavone C, Brusco S, Bertini M, et al. Current pharmacological treatments for COVID-19: what's next? Br J Pharmacol. 2020;177(21):4813–4824.
   PubMed Web of Science ®Google Scholar
• Lou Y, Liu L, Yao H, et al. Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. Eur J Pharm Sci. 2021;157:105631
   PubMed Web of Science ®Google Scholar
• Osborne V, Davies M, Lane S, et al. Lopinavir-ritonavir in the treatment of COVID-19: a dynamic systematic benefit-risk assessment. Drug Saf. 2020;43(8):809–821.
   PubMed Web of Science ®Google Scholar
• Chu CM. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–256.
   PubMed Web of Science ®Google Scholar
• de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875–4884.
   PubMed Web of Science ®Google Scholar
• Torequl IM, Nasiruddin M, Khan IN, et al. A perspective on emerging therapeutic interventions for COVID-19. Front Public Heal. 2020;8:281.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393
   PubMed Web of Science ®Google Scholar
• Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Matarrese D, et al. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. 2020;81(2):318–356.
   PubMed Web of Science ®Google Scholar
• Bian H, Zheng Z-H, Wei D, et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. medRxiv Prepr. 2020.
   Google Scholar
• Lane JCE, Weaver J, Kostka K, et al. Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol. 2020;2(11):e698–e711.
   PubMedGoogle Scholar
• Tiberghien P, Lamballerie X, Morel P, et al. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?. Vox Sang. 2020;115(6):488–494.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281–292.
   PubMed Web of Science ®Google Scholar
• Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020;46(5):854–887.
   PubMed Web of Science ®Google Scholar
• Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847.
   PubMed Web of Science ®Google Scholar
• Huang Y-H, Lei H-Y, Liu H-S, et al. Tissue plasminogen activator induced by dengue virus infection of human endothelial cells. J Med Virol. 2003;70(4):610–616.
   PubMed Web of Science ®Google Scholar
• Nahmias AJ, Kibrick S. Inhibitory effect of heparin on herpes simplex virus. J Bacteriol. 1964;87(5):1060–1066.
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis. 2020;34:101615.
   PubMed Web of Science ®Google Scholar